FDA Oncologic Drugs Advisory Committee unanimously recommends CARVYKTI® for relapsed/refractory multiple myeloma patients.

U.S. FDA Oncologic Drugs Advisory Committee unanimously recommends CARVYKTI® (ciltacabtagene autoleucel) for treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), and are refractory to lenalidomide, based on results from Phase 3 CARTITUDE-4 study.